Recombinant Human IFNA1 (IFN-alpha1)

• Description:

  All known subtypes of IFN- alpha show the same antiviral antiparasitic, antiproliferative activities. IFN-alpha forms are produced by monocytes/macrophages, lymphoblastoid cells, fibroblasts, and a number of different cell types following induction by viruses, nucleic acids, glucocorticoid hormones, and low-molecular weight substances. All IFN-alpha subtypes possess a common conserved sequence region between amino acid positions 115-151 while the amino-terminal ends are variable. Many IFN-alpha subtypes differ in their sequences at only one or two positions. IFN-alpha and IFN-beta are thought to bind to the same receptor. Signal transduction mechanisms elicited after binding of IFN-alpha to its receptors involves tyrosine phosphorylation of various non-receptor tyrosine kinases belonging to the Janus kinases.

• Gene Name:

  IFNA1

• Gene Aliases:

  Interferon alpha-D, IFN-alpha-1/13, LeIF D, IFNA13

• Gene ID:

  3439

• Accession Number:

  P01562

• Organism:

  Human

• Source:

  E. coli

• Concentration:

  <1.0 EU/μg of recombinant protein as determined by the LAL method

• Purity:

  >95% as determined by SDS-PAGE

• Molecular Weight:

  19.7

• Shipping Conditions:

  Ambient Temperature

• Storage Conditions:

  The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.

• Appearance:

  Lyophilized Powder

• Formulation:

  Lyophilized from a 0.2 μm filtered solution in Tris and NaCl (pH 8.0)

• CAS Number:

  9000-83-3